AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

Core Insights - AbbVie is set to present new data from its early oncology research at the upcoming AACR Annual Meeting, focusing on investigational molecules ABBV-969 and ABBV-514 for hard-to-treat tumors [1][4][12] - The company aims to advance innovative therapies for patients with difficult-to-treat cancers, emphasizing the importance of early-stage research in addressing unmet medical needs [1][9] AbbVie’s Investigational Therapies - ABBV-969 is a dual-targeted antibody-drug conjugate (ADC) designed to target tumor cells expressing STEAP1 and/or PSMA antigens, currently in Phase 1 clinical trials for metastatic castration-resistant prostate cancer (mCRPC) [1][7][12] - ABBV-514 is a novel CCR8-targeting antibody that shows promise in enhancing anti-tumor immunity and is being evaluated in Phase 1 trials for non-small cell lung cancer (NSCLC) and head and neck cancer [1][7][12] Research Focus Areas - Presentations will include analyses of treatment resistance and biomarker discovery based on real-world data, which are critical for developing precision medicine [1][5][12] - A study will explore the overlap of folate receptor alpha expression in ovarian cancers, potentially aiding in treatment matching and sequencing [5][12] - Another study will utilize multi-omics approaches to understand long-term responses and resistance to immunotherapy in NSCLC [5][12] Clinical Trials and Presentations - ABBV-969 data will be presented in an oral session on April 27, 2025, highlighting its potential as a first-in-class treatment for advanced prostate cancer [3][4] - ABBV-514 data will be showcased in a poster presentation on April 29, 2025, focusing on its ability to deplete immunosuppressive Tregs in tumors [3][4] - Additional presentations will cover various aspects of cancer research, including germline variants and their association with patient prognosis [5][12]